Stimulation of hyaluronan synthesis by interleukin-1beta involves activation of protein kinase C betaII in fibroblasts from patients with Graves' ophthalmopathy.
Hyaluronan accumulation in the retroorbital connective tissue is one of the pathological features of Graves' ophthalmopathy. Interleukin-1beta (IL-1beta) is known to stimulate hyaluronan synthesis in orbital fibroblasts. In the present study, the intracellular signal transduction pathways involved in this stimulatory effect were investigated in cultured human retroorbital fibroblasts from patients with Graves' ophthalmopathy. IL-1beta-induced hyaluronan synthesis was significantly inhibited by pretreatment of the cells with two protein kinase C (PKC) inhibitors, chlerythrine chloride and H-7. In addition, treatment with phorbol 12-myristate 13-acetate (PMA), a direct PKC activator, also resulted in increased hyaluronan production. IL-1beta- or PMA-stimulated hyaluronan synthesis was blocked by the protein synthesis inhibitor, cycloheximide. Moreover, the intracellular Ca(2+) concentration of the orbital fibroblasts was also involved in the IL-1beta induced transduction pathway, the effect being completely inhibited by BAPTA, an internal calcium chelator. In addition, A23187, a calcium ionophore, increased hyaluronan synthesis in unstimulated cells. These results suggest that the Ca(2+)-dependent PKC signal transduction pathway plays an important role in the IL-1beta-induced hyaluronan synthesis. Moreover, IL-1beta treatment resulted in increased PKC activity and the rapid translocation of PKC betaII from the cytoplasm to the plasma membrane. These results indicate that cytosolic Ca(2+) and PKC betaII are involved in IL-1beta-induced hyaluronan synthesis in cultured orbital fibroblasts from patients with Graves' ophthalmopathy.
Wong
Y K
YK
Department of Anatomy, School of Life Science/Medicine, National Yang Ming University, Taipei, Taiwan.
Tang
K T
KT
Wu
J C
JC
Hwang
J J
JJ
Wang
H S
HS
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002462:Cell Membrane / Q000201:enzymology / Q000473:pathology; D002478:Cells, Cultured; D003593:Cytoplasm / Q000201:enzymology; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism*; D006111:Graves Disease / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D006820:Hyaluronic Acid / Q000819:agonists* / Q000096:biosynthesis*; D007375:Interleukin-1 / Q000378:metabolism* / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008856:Microscopy, Fluorescence; D010703:Phorbol Esters / Q000494:pharmacology; D011493:Protein Kinase C / Q000032:analysis / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism*; D064546:Protein Kinase C beta; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; D021381:Protein Transport / Q000187:drug effects; D015398:Signal Transduction; D017871:Calcium-Calmodulin-Dependent Protein Kinases
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D002118:Calcium; D004533:Egtazic Acid; D006820:Hyaluronic Acid; D007375:Interleukin-1; D007527:Isoenzymes; D010703:Phorbol Esters; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; D017871:Calcium-Calmodulin-Dependent Protein Kinases; C008874:phorbol-12,13-diacetate; C025603:1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid